Home
About
Leadership
Technology
Pipeline
News
Careers
Contact

Recent Posts

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Archives

August 2023
May 2023
April 2023
January 2023
November 2022
October 2022
September 2022
June 2022
May 2022
April 2022
March 2022
January 2022
October 2021
September 2021
August 2021
May 2021
April 2021
February 2021
January 2021
December 2020
November 2020
June 2020

Categories

Press Releases

Archives

August 2023
May 2023
April 2023
January 2023
November 2022
October 2022
September 2022
June 2022
May 2022
April 2022
March 2022
January 2022
October 2021
September 2021
August 2021
May 2021
April 2021
February 2021
January 2021
December 2020
November 2020
June 2020

Category: Executives

Fred Aslan, M.D.

Jennifer Bush

Peter Flynn, Ph.D.

Thorsten Graef, M.D., Ph.D.

Christopher Horan

Eugene Helsel

John Lim, Pharm.D.

Heather Raymon, Ph.D.

Privacy Policy
Terms

© Artiva Biotherapeutics, Inc., 2023

Sign up for news updates

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy